Located on a large campus in Berlin, New Jersey, just twenty minutes from Philadelphia, Hassman Research Institute (HRI) is a leading clinical research organization that conducts studies in a wide variety of therapeutic areas. HRI’s highly trained and experienced staff, including four board certified clinical investigators, is dedicated to maintaining the highest standard of quality results in the trials they conduct.
On the HRI campus there are fourteen private practices led by physicians that serve as sub-investigators. Their specialties include psychiatry, addictions, abuse liability, neurology, cardiology, dermatology, ophthalmology, endocrinology, ear, nose and throat (ENT), gastroenterology, orthopedics, pain management, and obstetrics and gynecology (OBGYN). Through five multi-speciality practices owned by HRI, we have a database of over 70,000 subjects and access to numerous patient files. HRI conducts a full complement of inpatient and outpatient Phase I-V research trials and focuses on special populations including the elderly, patients facing addiction, and patients with psychiatric, neurological, and medical disorders. Additional specialized studies include pain models for new compound development, pain management, human abuse liability, hepatic/renal, and several additional therapeutic areas.
Led by Dr. Howard Hassman and Dr. Larry Ereshefsky, HRI is well-positioned to provide the scientific leadership and operational expertise needed to ensure the success of our clinical research. Our significant experience and proven track-record in managing complex single and multiple ascending trials, including the use of translationally meaningful pharmacodynamics (PD) biomarkers, can de-risk proof of concept studies. In Phase I, these combination trials can allow physicians to identify potential risks and threats to compound viability, as well as help them to implement strategies to overcome these challenges. We take pride not only in our therapeutic experience, but also in our commitment to building long-term partnerships.
HRI offers an outstanding team of experts who oversee the setup and conduct of each clinical study. Dr. Larry Ereshefsky is an internationally recognized thought leader in clinical translational central nervous system research. Dr. Howard Hassman has an extensive background in psychodynamic psychotherapy, pain management, psychopharmacology and addiction medicine. As Chief Scientific Officer, Dr. Hassman leads a highly-experienced team of Board Certified Investigators, Psychometric and Pain/Addiction Raters, Clinical Research Coordinators, and Quality Assurance and Regulatory Affairs Specialists. The HRI team is the backbone of our company and driving force behind meeting critical project deadlines while maintaining the highest standard of quality for pharmaceutical sponsors.
Two teams that are paramount to HRI’s success are our Patient Retention Team and Patient Outreach Team which provide support and education to enrolled patients and to our community. HRI plays an active role in the community by providing care options to those interested in clinical trials.
HRI has the experience, resources, and standards to conduct small and large clinical programs, while maintaining a “small company” feel that allows us to provide our clients and participants with individual attention and flexible, creative solutions.